Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144150 · ClinicalTrials.gov registry record · NA
EVERO Drug-coated Balloon (DCB) Randomized Trial
A NA study, sponsored by Cook Research Incorporated.
- Recruiting
- Registry status
- NA
- Development phase
- 410
- Enrollment target
NCT07144150: Recruiting NA study, sponsored by Cook Research Incorporated.
NCT07144150 is a NA study that is actively recruiting participants, run by Cook Research Incorporated. The registered enrollment target is 410 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07144150, a NA study, is actively recruiting participants, sponsored by Cook Research Incorporated.
- RECRUITING
- Registry status
- NA
- Development phase
- 410 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).
Primary Outcome
The primary safety endpoint is a composite assessment of freedom from device- or procedure-related death, freedom from target limb major amputation, and freedom from clinically-driven target lesion revascularization (CD-TLR)
Interventions
- COMBINATION_PRODUCT Evero DCB
- COMBINATION_PRODUCT Paclitaxel DCB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2032-10 |
| Phase | NA |
What NCT07144150 shows while recruiting
NCT07144150 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Evero DCB is the first listed.
NCT07144150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07144150 about?
NCT07144150 is a clinical study titled "EVERO Drug-coated Balloon (DCB) Randomized Trial". The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery l...
What is the current status of trial NCT07144150?
This trial is currently recruiting. It is a NA study. The enrollment target is 410 participants. The study started on 2026-04-17. Estimated completion is 2032-10.
What interventions are being tested in trial NCT07144150?
The interventions under investigation include: Evero DCB (COMBINATION_PRODUCT), Paclitaxel DCB (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07144150?
This trial is sponsored by Cook Research Incorporated, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07144150's enrollment target sits among peer trials
410 242nd of 2000 higher than 1,758 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI